Trepulmix 10 mg/ml solution for infusion

Trepulmix 10 mg/ml solution for infusion:

One ml of solution contains 10 mg treprostinil (as sodium salt).

Each 10 ml vial of solution contains 100 mg treprostinil (as sodium salt).

Excipients with known effect

Each 10 ml vial contains 37.4 mg (1.63 mmol) sodium. For the full list of excipients, see section 6.1.

Solution for infusion.

Clear colourless to slightly yellow solution, free from visible particles with a pH of 6.0 – 7.2 and an osmolality between 253 and 284 mOsm/kg.

Trepulmix is indicated for the treatment of adult patients with WHO Functional Class (FC) III or IV and:

- inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or

- persistent or recurrent CTEPH after surgical treatment to improve exercise capacity.

Treatment with Trepulmix should be initiated and monitored only by clinicians experienced in the treatment of pulmonary hypertension. Treatment should be initiated under close medical supervision in a medical setting able to provide intensive care.

Posology

The recommended initial infusion rate is 1.25 ng/kg/min. If this initial dose is poorly tolerated, the infusion rate should be reduced to 0.625 ng/kg/min.

Dose adjustments

The infusion rate should be increased under medical supervision in increments of up to 1.25 ng/kg/min per week for the first four weeks of treatment and then up to 2.5 ng/kg/min per week.

The dose should be adjusted on an individual basis and under medical supervision in order to achieve a maintenance dose at which symptoms improve and which is tolerated by the patient.

During the follow-up phase of a clinical trial in CTEPH patients, the mean doses reached after 12 months were 31 ng/kg/min, after 24 months 33 ng/kg/min, and after 48 months 39 ng/kg/min. The respective maximum doses observed in the clinical trial were 52 ng/kg/min, 54 ng/kg/min and 50 ng/kg/min respectively.

Abrupt withdrawal or sudden marked reductions in the dose of treprostinil may cause a rebound of symptoms of chronic thromboembolic pulmonary hypertension. It is therefore recommended that interruption of treprostinil therapy is avoided and that the infusion is re-started as soon as possible after an abrupt accidental dose reduction or interruption. The optimal strategy for reintroducing treprostinil infusion needs to be determined on a case by case basis by medically qualified personnel. In most cases, after an interruption of up to 4 hours, restarting of treprostinil infusion can be done using the same dose rate; interruptions for up to 24 hours may require a dose reduction of up to 50% of the most recent dose with a subsequent uptitration to the clinically effective dose. Longer periods of interruption may require the dose of treprostinil to be re-titrated from even lower flow rates. In any case, the reintroduction of treprostinil should be under medical supervision.

Special populations

Hepatic impairment

The initial dose of Trepulmix should be decreased to 0.625 ng/kg/min and incremental dose increases should be made cautiously (see section 5.2). Increments could be reduced to 0.625 ng/kg/min per dose increase, the final decision on the dose increments is at the discretion of the supervising physician.

Please note that “Severe hepatic impairment (Child-Pugh Class C) is listed as contraindication for use of treprostinil, see section 4.3.

Renal impairment

As no clinical studies have been carried out in patients with renal impairment, the treatment recommendations are not established for patients with renal impairment. As treprostinil and its metabolites are excreted mainly through the urinary route, caution is recommended when treating patients with renal impairment in order to prevent deleterious consequences related to the possible increase of systemic exposure.

Elderly

No pharmacokinetic data of treprostinil in elderly is available. Caution is recommended when treating elderly patients due to higher incidence of hepatic and / or renal impairment.

Obese patients

Therapy of obese patients (weight ≥ 30% above ideal weight) should be initiated and increased with doses calculated based on their ideal weight. See section 5.2 for more information.

Paediatric population

There is no relevant use of treprostinil in children and adolescents for the indication of CTEPH.

Method of administration

Trepulmix is for subcutaneous use. It is administered undiluted by continuous infusion via a subcutaneous catheter using an ambulatory infusion pump.

The healthcare professional responsible for the therapy must ensure that the patient is fully trained and competent to use the chosen infusion device. All patients must be trained in preparation of the treprostinil infusion reservoir and priming of the infusion delivery tubing and connection. Written guidance, either from the pump manufacturer or specially tailored advice by the prescribing physician must be made available to the patient. This includes the required normal drug delivery actions, advice how to manage occlusions and other pump alarms, and details whom to contact in an emergency.

In order to avoid interruptions in drug delivery, the patient must have access to a backup infusion pump and subcutaneous infusion sets in the event that the administration equipment should suffer an accidental malfunction.

The ambulatory infusion pump used to administer undiluted Trepulmix subcutaneously, should be:

• small and lightweight,

• capable of adjusting infusion rates in increments of 0.002 ml/h or less,

• fitted with occlusion, low battery, programming error and motor malfunction alarms,

• accurate to within +/- 6% of the programmed delivery rate

• positive pressure driven (continuous or pulsated).

The reservoir must be made of polypropylene or glass.

Patients must be thoroughly trained in the use and programming of the pump, and the connection and care of the infusion set.

Flushing the infusion line whilst connected to the patient may lead to accidental overdose. For more information on the symptoms and treatment of overdose please refer to Section 4.9 of this document.

Trepulmix is available at concentrations of 1, 2.5, 5 and 10 mg/ml.

For subcutaneous infusion, Trepulmix is delivered without further dilution at a calculated subcutaneous infusion rate (ml/h) based on a patient's dose (ng/kg/min), weight (kg), and the vial strength (mg/ml) of Trepulmix being used. During use a single reservoir (syringe) of undiluted Trepulmix can be administered up to 72 hours at 37°C. The subcutaneous infusion rate is calculated using the following formula:

*Conversion factor of 0.00006 = 60 min/hour x 0.000001 mg/ng

To avoid calculation errors due to the complex formula please check the dose calculation tables below. For each medicinal product strength one dose calculation table is available.

Example calculations for subcutaneous infusion are as follows:

Example 1:

For a 60 kg person at the recommended initial dose of 1.25 ng/kg/min using the 1 mg/ml Trepulmix Vial Strength, the infusion rate would be calculated as follows:

Example 2:

For a 65 kg person at a dose of 40 ng/kg/min using the 5 mg/ml Trepulmix Vial Strength, the infusion rate would be calculated as follows:

Table 1-1 provides guidance for subcutaneous infusion delivery rates of Trepulmix 1 mg/ml for patients of different body weights corresponding to doses of up to 42.5 ng/kg/min.

Table 1-1:

Infusion rate setting of subcutaneous pump (ml/h) for Trepulmix 1 mg/ml

The shaded areas indicate the highest infusion rate which is possible with a 3 ml syringe change every three days.

Table 1-2 provides guidance for subcutaneous infusion delivery rates of Trepulmix 2.5 mg/ml for patients of different body weights corresponding to doses of up to 42.5 ng/kg/min.

Table 1-2:

Infusion rate setting of subcutaneous pump (ml/h) for Trepulmix 2.5 mg/ml

The shaded areas indicate the highest infusion rate which is possible with a 3 ml syringe change every three days.

Table 1-3 provides guidance for subcutaneous infusion delivery rates of Trepulmix 5 mg/ml for patients of different body weights corresponding to doses of up to 80 ng/kg/min.

Table 1-3:

Infusion rate setting of subcutaneous pump (ml/h) for Trepulmix 5 mg/ml

The shaded areas indicate the highest infusion rate which is possible with a 3 ml syringe change every three days.

Table 1-4 provides guidance for subcutaneous infusion delivery rates of Trepulmix 10 mg/ml for patients of different body weights corresponding to doses of up to 155 ng/kg/min.

Table 1-4:

Infusion rate setting of subcutaneous pump (ml/h) for Trepulmix 10 mg/ml

Shaded areas indicate the highest infusion rate supported by a 3 ml syringe change every three days.

• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

• Pulmonary veno-occlusive disease.

• Severe decompensated left heart failure.

• Severe hepatic impairment (Child-Pugh Class C).

• Active gastrointestinal ulcer, intracranial haemorrhage, gastrointestinal injury or other gastrointestinal bleeding.

• Congenital or acquired valvular defects with clinically relevant myocardial dysfunction not related to pulmonary hypertension.

• Severe coronary heart disease or unstable angina

• Myocardial infarction within the last six months

• Severe arrhythmias

• Cerebrovascular events (e.g. transient ischaemic attack, stroke) within the last three months.

• Co-administration with other prostanoids

General therapy

The decision to initiate therapy with treprostinil should take into consideration the high probability that continuous infusion will have to be continued for a prolonged period. Thus the patient's ability to accept and to be responsible for an indwelling catheter and infusion device should be carefully considered. The clinical team responsible for the therapy must ensure that the patient is fully trained and competent to use the chosen infusion device (see section 4.2).

Treprostinil is a potent pulmonary and systemic vasodilator. In subjects presenting with low systemic arterial pressure, treprostinil treatment may increase the risk of systemic hypotension. Treatment is not recommended for patients with systolic arterial pressure of less than 85 mmHg.

It is recommended to monitor systemic blood pressure and heart rate during any change in dose with instructions to stop the infusion if symptoms of hypotension develop, or a systolic blood pressure of 85 mmHg or lower is detected.

If a patient develops pulmonary oedema while on treprostinil, the possibility of an concomitant pulmonary veno-occlusive disease should be considered. The treatment should be stopped as pulmonary veno-occlusive disease is a contraindication for therapy with treprostinil (see section 4.3).

Caution is advised in situations where treprostinil may increase the risk of bleeding by inhibiting platelet aggregation (see section 4.5 and 4.8).

Withdrawal

Abrupt withdrawal or sudden marked reductions in the dose of treprostinil may cause a rebound in pulmonary hypertension (see section 4.2).

Special populations

Patients with hepatic and renal impairment should be dosed cautiously (see section 4.2).

As treprostinil and its metabolites are excreted mainly through the urinary route, caution is recommended when treating patients with renal impairment in order to prevent deleterious consequences related to the possible increase of systemic exposure (see section 4.2).

Sodium content

Trepulmix 1 mg/ml solution for infusion

This medicinal product contains 36.8 mg sodium per 10 ml vial of 1 mg/ml, equivalent to 1.8% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

Trepulmix 2.5 mg/ml solution for infusion

This medicinal product contains 37.3 mg sodium per 10 ml vial of 2.5 mg/ml, equivalent to 1.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

Trepulmix 5 mg/ml solution for infusion

This medicinal product contains 39.1 mg sodium per 10 ml vial of 5 mg/ml, equivalent to 2.0% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

Trepulmix 10 mg/ml solution for infusion

This medicinal product contains 37.4 mg sodium per 10 ml vial of 10 mg/ml, equivalent to 1.9% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

To be taken into consideration by patients on a controlled sodium diet.

Concomitant medicinal products

Concomitant administration of cytochrome P450 (CYP2C8) enzyme inhibitors (as gemfibrozil) may lead to increased exposure (both C_max and AUC) to treprostinil. With an increased exposure there is a likelihood of a higher incidence of adverse events associated with the administration of treprostinil. Therefore, a dose reduction should be considered (see section 4.5).

Concomitant administration of CYP2C8 enzyme inducers (for example rifampicin) may result in a decreased exposure to treprostinil. At a reduced exposure, it is likely to have decreased clinical efficacy. Therefore, a higher dose of treprostinil is to be considered (see section 4.5).

Concomitant administration with diuretics, antihypertensive agents, or other vasodilators

Concomitant administration of treprostinil with diuretics, antihypertensive agents or other vasodilators increases the risk of systemic hypotension.

Concomitant administration with platelet aggregation inhibitors, including NSAIDs and anticoagulants

Treprostinil may inhibit platelet function. Concomitant administration of treprostinil with platelet aggregation inhibitors, including NSAIDs, nitric oxide donors or anticoagulants may increase the risk of bleeding. Surveillance of patients taking anticoagulants should be closely maintained. The concomitant use of other platelet inhibitors should be avoided in patients taking anticoagulants.

Concomitant administration with cytochrome P450 (CYP2C8) enzyme inducers/inhibitors

Gemfibrozil and other CYP2C8 inhibitors

Pharmacokinetic studies in humans with oral treprostinil diolamine indicated that the concomitant administration of cytochrome P450 (CYP2C8) enzyme inhibitor gemfibrozil doubles the exposure (both C_max and AUC) to treprostinil. In case a CYP2C8 inhibitor (e.g. gemfibrozil, trimethoprim and deferasirox) is added to or omitted from the patient's treatment after the titration phase, a dose adjustment of treprostinil has to be considered.

Rifampicin and other CYP2C8 inducers

Pharmacokinetic studies in humans with oral treprostinil diolamine indicated that the concomitant administration of CYP2C8 enzyme inducer rifampicin resulted in a reduced (by about 20%) exposure to treprostinil. In case rifampicin is added to or omitted from the patient's treatment after the titration phase, a dose adjustment of treprostinil has to be considered.

Also other CYP2C8 inducers (e.g. phenytoin, carbamazepine, phenobarbital and St. John's Wort) may lead to reduced exposure to treprostinil. In case a CYP2C8 inhibitor is added to or omitted from the patient's treatment after the titration phase, a dose adjustment of treprostinil has to be considered.

Concomitant administration with bosentan

In a pharmacokinetic study in humans, in which bosentan (250 mg/day) and treprostinil diolamine (oral dose of 2 mg/day) were administered concomitantly, no pharmacokinetic interaction between treprostinil and bosentan was observed.

Concomitant administration with sildenafil

In a pharmacokinetic study in humans, in which sildenafil (60 mg/day) and treprostinil diolamine (oral dose of 2 mg/day) were administered concomitantly, no pharmacokinetic interaction between treprostinil and sildenafil was observed.

Pregnancy

There are no or limited amount of data from the use of treprostinil in pregnant women. Animal studies are insufficient with respect to effects on pregnancy (see section 5.3). Treprostinil should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the foetus.

Women of child-bearing potential

Contraception is recommended during treprostinil treatment.

Breast-feeding

It is not known whether treprostinil is excreted in human milk. Breastfeeding women taking treprostinil should be advised to discontinue breastfeeding.

Treprostinil has minor influence on the ability to drive and use machines at the initiation of treatment or dose adjustments. They may be accompanied by undesirable effects such as symptomatic systemic hypotension or dizziness which may impair ability to drive and operate machinery.

Summary of safety profile

In addition to local effects resulting from the administration of treprostinil by subcutaneous infusion such as infusion site pain and infusion site reaction, adverse reactions with treprostinil are related to the pharmacological properties of prostacyclins.

Tabulated summary of adverse reactions

The adverse reactions are presented as MedDRA preferred terms under the MedDRA system organ class. The incidence of the adverse reactions below are expressed according to the following categories: Very common (≥1/10); common (≥1/100 to<1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).

Description of selected adverse reactions

Bleeding events

Due to its effects on platelet aggregation, treprostinil may increase the risk of bleeding, as observed by an increased incidence of epistaxis and gastrointestinal (GI) bleeding (including GI haemorrhage, rectal haemorrhage, gum haemorrhage and melaena) in controlled clinical trials in PAH.

Events Observed During Clinical Practice:

In addition to adverse reactions reported from clinical trials in PAH patients, the following events have been identified during post-approval use of treprostinil in other indications. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The following events were reported: infusion site infection, subcutaneous infusion site abscess formation, thrombocytopenia, and bone pain.

In addition, generalised rashes, sometimes macular or papular in nature, and cellulitis have been infrequently reported.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Symptoms of overdose with treprostinil include flushing, headache, hypotension, nausea, vomiting, and diarrhoea. Patients experiencing symptoms of overdose should, after consultation with their physician, immediately reduce their dose of treprostinil depending on the severity of the symptoms until the symptoms of overdose have resolved. Dosing should be recommenced with caution under medical control and patients monitored closely for recurrence of unwanted symptoms.

No antidote is known.

Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excl. heparin

ATC code: B01AC21

Mechanism of action

Treprostinil is a prostacyclin analogue.

It exerts a direct vasodilation effect on the pulmonary and systemic arterial circulation and, inhibits platelet aggregation.

Clinical efficacy and safety

In a randomised, multi-centre, controlled clinical trial, a total of 105 male (53.3%) and female (46.7%) adult patients with inoperable CTEPH or persistent or recurrent CTEPH after pulmonary endarterectomy (18-88 years of age, mean 64 years) were treated. Patients were required to have CTEPH classified as severe, as defined by an un-encouraged six-minute walk test (6MWT) of between 150 and 400 meters and a classification in the WHO/NYHA functional class III or IV. Patients were divided into two treprostinil treatment groups (53 high dose and 52 low dose patients, treated with subcutaneous infusion for a total of 24 weeks) as follows. In the high dose group, patients were administered a subcutaneous dose via infusion pump that increased from approximately 1 to a target dose of approximately 30 ng/kg/min for the first 12 weeks, followed by 12 weeks of stable perfusion; in the low dose group, the target dose was approximately 3 ng/kg/min following the same schedule.

The primary efficacy analysis was based on the individual difference between the 6MWT data at baseline and after 24 weeks. Treprostinil improved the six-minute walk distance (6MWT, six-minute walk test: baseline vs. 24 weeks of treatment) by a mean of 45.43 m in the high dose group versus 3.83 m in the low dose group (p<0.05, ANCOVA). Exploratory secondary efficacy (low vs. high) measures, after 24 weeks of treatment, showed -significant improvements in New York Heart Association functional (NYHA) class, haemodynamic parameters (mean pulmonary vascular resistance, mean pulmonary arterial pressure, mean cardiac output, and mean cardiac index) and median pro-BNP (brain natriuretic peptide values) in favor of the high dose group. No significant differences between the two test groups in the number of patients showing a "clinical worsening", defined as a reduction of 6MWD of 20% compared to baseline, worsening of NYHA functional class and/or hospitalisation due to CTEPH with the need of additional pulmonary hypertension specific treatment, were observed. High dose treprostinil showed no significant changes in the Borg Dyspnoea Score (measured during the 6MWT), or the summed Quality of Life score as assessed by the Minnesota Living with Heart Failure Questionnaire.

Distribution

In humans, steady-state plasma concentrations are usually achieved within 15 to 18 hours of the initiation of either subcutaneous or intravenous infusion of Treprostinil. Steady-state plasma concentrations of treprostinil are dose-proportional at infusion rates of 2.5 up to 125 ng/kg/min.

The mean apparent elimination half-life following subcutaneous administration ranged from 1.32 to 1.42 hours after infusions over 6 hours, 4.61 hours after infusions over 72 hours, and 2.93 hours after infusions lasting at least three weeks. The mean volume of distribution for treprostinil ranged from 1.11 to 1.22 l/kg, and plasma clearance ranged from 586.2 to 646.9 ml/kg/h. Clearance is lower in obese subjects (BMI > 30 kg/m²).

In a seven-day chronic pharmacokinetic study in 14 healthy volunteers with treprostinil doses ranging from 2.5 to 15 ng/kg/min administered by subcutaneous infusion, steady state plasma treprostinil concentrations reached peak levels twice (at 1 a.m. and 10 a.m. respectively) and trough levels twice (at 7 a.m. and 4 p.m. respectively). The peak concentrations were approximately 20% to 30% higher than the trough concentrations.

Elimination

In a study conducted on healthy volunteers using [¹⁴C] radioactive treprostinil, 78.6% and 13.4% of the subcutaneous radioactive dose were recovered in the urine and faeces respectively over a period of 224 hours. No single major metabolite was observed. Five metabolites were detected in the urine, ranging from 10.2% to 15.5% of the dose administered. These five metabolites accounted for a combined total of 64.4%. Three are products of oxidation of the 3-hydroxyloctyl side chain, one is a glucuroconjugated derivative (treprostinil glucuronide) and one is unidentified. Only 3.7% of the dose was recovered in the urine as unchanged parent drug.

An in vitro study demonstrated no inhibitory potential of treprostinil to human hepatic microsomal cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A).

Moreover, administration of treprostinil had no inducing effect on hepatic microsomal protein, total cytochrome (CYP) P 450 content or on the activities of the isoenzymes CYP1A, CYP2B and CYP3A.

Hepatic Insufficiency

In patients with portopulmonary hypertension and mild (n=4) or moderate (n=5) hepatic insufficiency, treprostinil at a subcutaneous dose of 10 ng/kg/min for 150 minutes had an AUC 0-24 h that was increased 260 % and 510 %, respectively, compared to healthy subjects. Clearance in patients with hepatic insufficiency was reduced by up to 80% compared to healthy adults (see section 4.2).

Elderly patients

In a multivariate analysis of pooled studies, patients in the age group ≥65 years had a small reduction in plasma clearance of treprostinil. However, most publications regarded either healthy volunteers or patient with PAH. CTEPH patients were rarely described. Age stratification was not performed in any publication. As only few studies reported on PK parameters but none reported both on CTEPH indication and PK data, no information is available on the pharmacokinetics of treprostinil in elderly patients.

Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and toxicity to reproduction.

In 13 and 26 week studies continuous subcutaneous infusions of treprostinil sodium caused infusion site reactions in rats and dogs (oedema/erythema, masses/swellings, pain/sensitivity to touch). In dogs severe clinical effects (hypoactivity, emesis, loose stool and infusion site oedema) and death (associated with intestinal intussusceptions and rectal prolapse) were observed in animals administered ≥300 ng/kg/min. Mean steady state plasma treprostinil levels of 7.85 ng/ml were measured in these animals. Plasma levels of this order may be achieved in humans treated with treprostinil infusions at >50 ng/kg/min.

As a continuously sufficient exposure to treprostinil has not been proven for any dosage tested in the reproductive studies in rats, these studies might be insufficient regarding possible effects on fertility, prenatal and postnatal development.

No long-term animal studies have been performed to evaluate treprostinil's carcinogenic potential.

Sodium citrate

Hydrochloric acid

Metacresol

Sodium hydroxide

Sodium chloride

Water for injections

This medicinal product must not be mixed with other medicinal products.

Unopened vial 3 years

After first opening 30 days

During use with continuous subcutaneous infusion

Chemical, physical and microbial in-use stability of a single container (syringe) of undiluted Trepulmix administered subcutaneously has been demonstrated for 72 h at 37°C.

This medicinal product does not require any special storage conditions.

For in-use storage times and conditions see section 6.3.

Trepulmix, 10 mg/ml solution for infusion: 10 ml type I clear glass vial sealed with a rubber teflon- coated stopper and fitted with a red cap.

Each carton contains one vial.

Not all pack sizes may be marketed.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

SciPharm Sàrl

7, Fausermillen

L-6689 Mertert

Luxembourg

PLGB 51174/0004

Date of first authorisation: 01 January 2021

28/02/2022